
    
      The study is composed of two phase 2 randomized multi-center substudies:

        -  PREDATOR-BR: to investigate the role of daratumumab in the setting of biochemical
           relapse

        -  PREDATOR-MRD: to investigate the role of daratumumab in minimal residual disease (MRD)
           reappearance
    
  